Sahay Lab is engineering lipid-based nanoparticles for delivery of mRNA based therapeutics
We just announced the primary efficacy analysis in the Phase 3 COVE study for mRNA-1273, our COVID-19 vaccine candidate and that today, we plan to request an Emergency Use Authorization from the U.S. FDA & conditional approval from the EMA. Read more: https://buff.ly/2Jt56Fz
Politics, Science and the Remarkable Race for a Coronavirus Vaccine - The New York Times
Politics, Science and the Remarkable Race for a Coronavirus Vaccine
The furious race to develop a coronavirus vaccine played out against a presidential election, between a pharmaceutical giant and a biotech upstart, wi...
On serious note. This news might appear old but it’s just few days old. Moderna says COVID-19 vaccine is 94.5% effective in preliminary analysis
Moderna says COVID-19 vaccine is 94.5% effective in preliminary analysis
It’s good news for the COVID-19 vaccine race and mRNA vaccine technology
Hilarious and scientifically spot on!
Nation Can’t Believe They Spent So Long Overlooking Obvious Solution Of mRNA Instructions For Spike Protein Encapsulated In Lipid Nanoparticle https://bit.ly/2UMZjNu
Excited for my keynote talk at the 'Global Virtual Summit on Biotechnology & Bioengineering' today on my research conducted at the Sahay Lab on Boosting Intracellular Delivery of mRNA Therapeutics.
#biotech #biotechnology #research #mrna #lipidnanoparticle